Intravenous infusions of TriN 2755, a new alkylating agent, inhibit the growth of human MDA-MB-231 breast tumour in Nude rats

Authors: Marc Hillairet de Boisferon, Zina Koob, Francis Bichat, Georg Ludwig, Wolfgang Barth
Oncodesign, Therapeutics

Abstract: The new cytotoxic anti-neoplastic agent TriN 2755, containing a triazene unit with alkylating properties, exhibited a potent antitumour activity in a large panel of human xenograft tumour models in mice when dosed by IV bolus injection. In rat, dog and mini pig toxicity studies, TriN 2755 demonstrated a favourable safety profile.
Here, we present efficacy data of TriN 2755 intravenously injected in the MDA-MB-231 tumour bearing Nude rat model.

Read the poster here